Table 3.
Associations between TLR3 and TNFRSF1 and breast cancer risk, by ER/PR tumor phenotype.
| Controls | ER+/PR+ | ER+/PR− | ER−/PR+ | ER−/PR− | Multinomial P-values (raw; adjusted)2,3 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| N | N | OR1 (95% CI) | N | OR (95% CI) | N | OR (95% CI) | N | OR (95% CI) | ||
| TLR3 (rs5743305)4 | 0.011, 0.040 | |||||||||
| TT | 1321 | 528 | 1.00 | 101 | 1.00 | 10 | 1.00 | 157 | 1.00 | |
| TA | 1415 | 597 | 1.04 (0.91, 1.20) | 106 | 0.97 (0.73, 1.29) | 21 | 1.98 (0.93, 4.23) | 201 | 1.20 (0.96, 1.50) | |
| AA | 430 | 172 | 0.97 (0.79, 1.19) | 28 | 0.82 (0.53, 1.27) | 12 | 3.70 (1.58, 8.67) | 57 | 1.11 (0.80, 1.53) | |
| P-value (raw; adjusted) 2 | 0.774, 1.000 | 0.387, 1.000 | 0.003,0.010 | 0.534, 1.000 | ||||||
| TNFRSF1A (rs4149578)4 | 0.018, 0.053 | |||||||||
| GG | 2487 | 1000 | 1.00 | 184 | 1.00 | 33 | 1.00 | 350 | 1.00 | |
| GA/AA | 678 | 295 | 1.09 (0.93, 1.27) | 50 | 0.99 (0.72, 1.38) | 10 | 1.13 (0.55, 2.30) | 64 | 0.67 (0.51, 0.89) | |
| P-value (raw; adjusted) | 0.284, 0.851 | 0.971, 1.000 | 0.747, 1.000 | 0.006, 0.017 | ||||||
1
Odds Ratios (OR) and 95% Confidence Intervals (CI) adjusted for age, study, BMI during referent year, parity, and genetic ancestry.
2
P values for SNPs in table are unadjusted and adjusted for multiple comparisons using the step down Bonferroni correction.
3
Multinomial p values exclude controls.
4
ARTP p value for TLR3 for ER−/PR+ tumors was 0.011; ARTP p value for ER−/PR− tumors for TNFRSF1A was 0.023.